Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma.
Chun-Ting HuShao-Jun PeiJing-Long WangLi-Dong ZuWei-Wei ShenLin YuanFeng GaoLi-Ren JiangStephen S-T YauGuo-Hui FuPublished in: Cancer chemotherapy and pharmacology (2023)
Our findings provide for the first time a detailed proteomics profile of current protein alterations in patients before anti-HER2 therapy and present a novel and optimal predictor for the response to trastuzumab treatment. HER2-positive GC patients with low expression of p-RPS6 are more likely to benefit from trastuzumab therapy than those with high expression. However, those with high expression of p-RPS6 may benefit from trastuzumab in combination with RPS6 phosphorylation inhibitors.
Keyphrases
- poor prognosis
- epidermal growth factor receptor
- metastatic breast cancer
- end stage renal disease
- binding protein
- mass spectrometry
- chronic kidney disease
- newly diagnosed
- high resolution
- single cell
- peritoneal dialysis
- bone marrow
- mesenchymal stem cells
- small molecule
- tyrosine kinase
- label free
- cell therapy
- protein protein
- patient reported